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Introduction
Hyperuricemia is commonly seen in association
with obesity, dyslipidemia, glucose intolerance, and
hypertension,1,2 a cluster of metabolic risk factors that
characterize the metabolic syndrome.3 Lakka et al4
reported that cardiovascular mortality was increased
2–3-fold in middle-aged men with the metabolic
syndrome. Several studies have shown that increased
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serum uric acid (UA) levels were also associated with
risk for cardiovascular disease.5,6 The resemblance of
hyperuricemia and the metabolic syndrome has led to
the suggestion that the metabolic syndrome can be
further expanded to include hyperuricemia.7,8 However,
the role of UA in the diagnosis of the metabolic
syndrome has not been established. The recent revised
version for the diagnosis of the metabolic syndrome
from the Adult Treatment Panel III (ATP III) of the
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National Cholesterol Education Program (NCEP)
has identified several components, which did not
include hyperuricemia.3 Bonora et al9 suggested that
obesity played a major role in linking hyperuricemia
with cardiovascular risk factors. Clausen et al10 found
that the association between UA and the metabolic
syndrome might be secondary to the association with
dyslipidemia. Since most persons with the metabolic
syndrome in clinical practice carry multiple risk
factors,3 we hypothesize that hyperuricemia may not
be required for the diagnosis of the metabolic syndrome.
The purpose of this study is to examine the contribution
of UA as an additional component of the metabolic
syndrome in middle-aged men. We are also interested
in investigating patterns underlying the co-occurrence
of components of the metabolic syndrome by using
factor analysis.
Methods
Subjects
From October 2002 to January 2003, 393 middle-
aged Chinese men were recruited for this study
consecutively from the Clinical Prevention Service
Program at the Taipei Veterans General Hospital
(VGH), a university teaching hospital with 2,700
inpatient beds. It is a professional health evaluation
program with more than 8,000 participants per year.
About 500 male participants, aged 45–60 years, were
registered during the study period. We excluded the
patients with known history of diabetes or with
hypertension under medical control. Those with fasting
plasma glucose (PG) higher than 126 mg/dL were
also excluded from the study. The eligible participants
were subjected to clinical examinations after a 10-hour
overnight fast.
Clinical examinations
Each subject received anthropometric measurements
performed by the same group of technicians at 08:00.11
Body height (BH) was measured to the nearest
millimeter, and body weight (BW) was measured to
the nearest 0.1 kg. Body mass index (BMI) was
calculated as BW divided by BH squared (kg/m2).
Waist circumference (WC) was measured at the level
of the umbilicus to the nearest millimeter by an
anthropometric tape (kp 1508; King-Life, Taipei,
Taiwan). Supine blood pressure (BP) was taken twice
after 10 minutes of rest by a sphygmomanometer
(Baumanometer; W. A. Baum Co Inc, Copiague, NY,
USA) at 1-minute intervals.12 The sphygmomanometer
was used with an initial pressure of 30 mmHg above
the pulse obliteration pressure and the systolic and
diastolic BP were determined to the nearest 2 mmHg
by phase I and V of the Korotkoff sounds. Fasting
blood samples were collected for the measurements of
PG, serum UA, lipid profile, and other biochemical
parameters.
Measurements
PG was measured by a glucose oxidase method in a
glucose analyzer (model 2300; YSI, Yellow Springs,
OH, USA). Total cholesterol (TC), total triglyceride
(TG), serum creatinine (Cr), alanine aminotransferase
(ALT), and UA levels were measured by using assay
kits (Boehringer Mannheim GmbH, Mannheim,
Germany) in an automatic blood chemistry analyzer
(Model 736; Hitachi, Tokyo, Japan). Serum high-
density lipoprotein cholesterol (HDL-C) was
determined by an enzymatic cholesterol assay after
dextran sulfate precipitation. The reference values for
Cr are 0.7–1.5 mg/dL and for ALT 0–40 U/L in men.
Statistical analysis
We divided the participants into 2 groups according to
their serum UA levels: those with UA < 7.0 mg/dL
and those with UA * 7.0 mg/dL.13 The metabolic
syndrome was defined by the 2005 version of the
NCEP ATP III criteria for Asian men.3,14 The diagnosis
of metabolic syndrome was made when participants
had 3 or more of the following: fasting PG * 100 mg/
dL, TG * 150 mg/dL, HDL-C < 40 mg/dL, BP *
130/85 mmHg, or WC * 90 cm.3,14 Continuous data
were expressed as mean ( SD or median (range). As
there was substantial skewing of TG and ALT values,
Mann-Whitney U tests were applied to the data of TG
and ALT for comparison of differences between groups.
Two sample t tests were applied to other continuous
data, and r2 tests to categorical data to compare the
differences between groups, respectively. Pearson
correlation coefficients were used to evaluate
correlations between UA and the components of the
metabolic syndrome. Logarithmic transformation
(Log) of TG values was applied to subordinate the
skewness of TG data in the Pearson analysis; this was
also followed for Log ALT in the regression analysis.
A stepwise multiple logistic regression analysis was
performed to examine the relationship between UA
and the diagnosis of metabolic syndrome. Participants
with or without the metabolic syndrome were dummy-
coded and used as dependent variables. UA, BMI, age,
Cr, Log ALT, WC, PG, TG, HDL-C, and systolic BP
were entered into the regression model as independent
variables. A p value of less than 0.05 was considered
statistically significant.
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Factor analysis using the principal component
method with Varimax rotation was performed to
examine if UA is clustered with other components of
the metabolic syndrome. Variables included in the
factor analysis were BMI, WC, PG, Log TG, HDL-C,
systolic BP, diastolic BP, and all with eigenvalues
greater than 1. Log TG values were used in the analysis
for a better fit for models. A factor loading with an
absolute value of ( 0.4 or greater was used as cut-off
values for data interpretation. The factor analysis was
performed again with the above variables and UA to
evaluate the contribution of UA to the variance
explained in the analysis.
Results
The clinical characteristics of the study participants are
shown in Table 1. We identified more subjects with
the metabolic syndrome in participants with
hyperuricemia (UA * 7.0 mg/dL) than those with
fasting UA < 7.0 mg/dL. The hyperuricemic subjects
had larger BMI, wider WC, higher PG and TG,
and lower HDL-C levels than their counterparts.
There were no significant differences in systolic
and diastolic BP between the 2 groups. The
hyperuricemic subjects also had higher serum levels of
ALT and Cr. Table 2 shows the correlations between
serum UA levels and the components of the metabolic
syndrome. UA was positively correlated with BMI,
WC, PG, Log TG, diastolic BP, and negatively
correlated with HDL-C. It was also positively correlated
with Log ALT (r = 0.12, p = 0.014) and serum Cr
levels (r = 0.27, p < 0.0001). The results of the
stepwise multiple logistic regression analysis are
reported in Table 3. The diagnosis of the metabolic
syndrome was significantly associated with ALT and
the original components of the syndrome (i.e. WC,
PG, TG, HDL-C, and systolic BP). However, we
could not demonstrate a significant association between
UA and the diagnosis of the metabolic syndrome in
the analysis. If we used serum UA * 7.0 mg/dL as a
cut-off point for the diagnosis of the metabolic
syndrome, the sensitivity would be 58.0% and the
specificity would be 55.3%.
Two-factor analysis models were analyzed to explore
the contribution of UA as an additional component to
the metabolic syndrome. The first model included the
Table 1. Descriptive characteristics of study participants by serum uric acid levels
UA < 7.0 mg/dL UA * 7.0 mg/dL p*
n 205 188
Age, yr 51.6 ( 4.3 51.5 ( 4.3 0.777
BH, cm 168.7 ( 5.6 169.3 ( 5.5 0.300
BW, kg 68.8 ( 8.1 73.1 ( 10.1 < 0.0001
BMI, kg/m2 24.2 ( 2.7 25.5 ( 3.0 < 0.0001
WC, cm 84.6 ( 6.9 88.5 ( 7.9 < 0.0001
UA, mg/dL 5.9 ( 0.8 7.9 ( 0.8 < 0.0001
PG, mg/dL 99 ( 9 102 ( 9 0.002
TG, mg/dL 111 (732) 133 (787) 0.001
Log TG 2.08 ( 0.23 2.13 ( 0.21 0.011
TC, mg/dL 208 ( 38 212 ( 39 0.316
HDL-C, mg/dL 49 ( 13 47 ( 10 0.021
Systolic BP, mmHg 123 ( 14 126 ( 14 0.141
Diastolic BP, mmHg 81 ( 10 83 ( 10 0.059
ALT, U/L 23 (123) 27 (362) 0.001
Log ALT 1.39 ( 0.21 1.46 ( 0.24 0.010
Cr, mg/dL 1.0 ( 0.1 1.1 ( 0.2 < 0.0001
Metabolic syndrome,† % 24.9 40.4 0.001
Data are expressed as mean ( SD or median (range). BH = body height; BW = body weight; BMI = body mass index; WC = waist circumference;
UA = uric acid; PG = fasting plasma glucose; TG = fasting total triglyceride; Log TG = logarithmic transformation of TG; TC = fasting total cholesterol;
HDL-C = high-density lipoprotein cholesterol; BP = blood pressure; ALT = alanine aminotransferase; Log ALT = logarithmic transformation of ALT;
Cr = creatinine.
*Mann-Whitney U tests were applied to TG and ALT. Two-sample t tests were used to compare other continued data and r2 tests to the categorized
data for the differences between the 2 groups.
†The metabolic syndrome was defined by the 2005 revised version of the National Cholesterol Education Program Adult Treatment Panel III criteria
for Asian men.
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original components of the syndrome without UA
(Table 4), and the second model added UA to the
variables of interest loaded in the first model (Table 5).
In the first model, 2 factors were identified. The first
factor, a metabolic factor, included positive loadings
for BMI, WC, PG, and Log TG, and negative loading
for HDL-C. This factor explained 36.2% of the total
variance of our study. Positive loadings for systolic and
diastolic BP were identified in the second factor,
designated as a BP factor. This factor explained an
additional 26.2% of the variance. In model 2, a
metabolic factor resembled that of model 1 with the
addition of a positive loading of UA to the factor.
Systolic and diastolic BP still loaded together as a BP
factor. This model explained a slightly smaller
proportion of the total variance (56.9%) than model 1
did (62.5%).
Table 4. Results of factor analysis with Varimax rotation:
factors and factor loadings without UA
Factors
Metabolic BP
BMI 0.82 * 0.14
WC 0.82 0.17
PG 0.53 0.13
Log TG 0.66 –0.01
HDL-C –0.69 0.11
Systolic BP 0.05 0.94
Diastolic BP 0.10 0.94
Proportion of variance explained, % 36.2 26.2
Total variance explained, % 36.2 62.5
BMI = body mass index; WC = waist circumference; PG = fasting plasma
glucose; TG = fasting total triglyceride; Log TG = logarithmic transformation
of TG; HDL-C = high-density lipoprotien cholesterol; BP = blood pressure.
*Loading * 0.40 in bold type.
Table 5. Results of factor analysis with Varimax rotation:
factors and factor loadings with UA
Factors
Metabolic BP
BMI 0.80 * 0.14
WC 0.81 0.16
PG 0.52 0.12
Log TG 0.65 –0.02
HDL-C –0.68 0.11
Systolic BP 0.06 0.94
Diastolic BP 0.10 0.94
UA 0.50 0.07
Proportion of variance explained, % 34.0 23.0
Total variance explained, % 34.0 56.9
BMI = body mass index; WC = waist circumference; PG = fasting plasma
glucose; TG = fasting total triglyceride; Log TG = logarithmic transformation
of TG; HDL-C = high-density lipoprotien cholesterol; BP = blood pressure.
*Loading * 0.40 in bold type.
Table 2. Pearson correlation coefficients of uric acid (mg/dL)
with components of the metabolic syndrome and indicated
variables in middle-aged Chinese men (n = 393)
Pearson
r p
BMI, kg/m2 0.27 < 0.0001
WC, cm 0.29 < 0.0001
PG, mg/dL 0.21 < 0.0001
Log TG 0.24 < 0.0001
TC, mg/dL 0.08 0.126
HDL-C, mg/dL –0.23 < 0.0001
Systolic BP, mmHg 0.09 0.089
Diastolic BP, mmHg 0.11 0.031
BMI = body mass index; WC = waist circumference; PG = fasting plasma
glucose; TG = fasting total triglyceride; Log TG = logarithmic transformation
of TG; TC = fasting total cholesterol; HDL-C = high-density lipoprotein
cholesterol; BP = blood pressure.
Table 3. Results of the stepwise logistic regression analysis with the diagnosis of metabolic syndrome* as the
dependent variable (n = 393)
Variables Exp(B)† 95% CI p
Log ALT 7.87 1.47–42.21 0.016
WC 1.20 1.11–1.29 < 0.001
PG 1.13 1.08–1.19 < 0.001
TG 1.02 1.01–1.03 < 0.001
HDL-C 0.89 0.84–0.94 < 0.001
Systolic BP 1.06 1.03–1.09 < 0.001
95% CI = 95% confidence interval; ALT = alanine aminotransferase; Log ALT = logarithmic transformation of ALT; WC = waist circumference;
PG = fasting plasma glucose; TG = fasting total triglyceride; Log TG = logarithmic transformation of TG; HDL-C = high-density lipoprotein cholesterol;
BP = blood pressure.
*The metabolic syndrome was defined by the 2005 revised version of the National Cholesterol Education Program Adult Treatment Panel III criteria
for Asian men.
†The results showed estimates for participants with the metabolic syndrome versus those without it. Variables included in the model were uric acid,
body mass index, age, creatinine, ALT, WC, PG, TG, HDL-C, and systolic BP.
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Discussion
The diagnosis criteria for the metabolic syndrome
proposed by the ATP III have resulted in more
discussion of components of the syndrome.15 Zavaroni
et al7 suggested hyperuricemia to be an additional
component of the metabolic syndrome. The American
Association of Clinical Endocrinologists once posted
hyperuricemia as a major criterion for the metabolic
syndrome.16 Our data show that the contribution of UA
as an additional component of the metabolic syndrome
seems to be insignificant in middle-aged men.
In the stepwise logistic regression approach, UA
levels were not associated with the diagnosis of the
syndrome (Table 3). Bonora et al9 revealed in the
Verona Young Men Study that BMI and TG were
independent predictors of UA concentrations. Yano
and colleagues17 found that BW was correlated
with UA most in more than 6,000 men without
using antihypertensive medication. Because UA
concentrations could be explained by components of
the metabolic syndrome (Table 2), it is possible that
there was a lack of association between UA and the
diagnosis of the metabolic syndrome. Besides, the
sensitivity and specificity of hyperuricemia for the
diagnosis of the metabolic syndrome were both below
60% in the study. UA levels seem to be short of
predictive power over the diagnosis of the syndrome
for these participants.
Factor analysis is a multivariate correlation
technique that has been used to understand underlying
patterns among variables of the metabolic syndrome.18
Meigs18 reviewed a dozen studies using factor
analysis to explore the underlying structure of the
metabolic syndrome and found that the syndrome
was composed of 2–4 domains of phenotypes. An
obesity-dyslipidemia-hyperinsulinemia domain is the
central feature of the syndrome, and a separate factor
for BP is loosely associated with the core feature.18
Our results accord with the previous reports. We
identified 2 domains of phenotypes of the metabolic
syndrome by factor analysis in the study: a metabolic
factor explained one third of variance, and a BP factor
accounted for another 25% of the variance (Table 4).
The joint occurrence of the metabolic factor and the
BP factor defines a case of the metabolic syndrome.
Several earlier analyses have investigated the role of
UA in the metabolic syndrome. In a cohort of white
males, UA was found to be loaded on a factor also
associated with plasma insulin, PG, TG and BMI,
but not with BP.19 In the Miami Community Health
Study on 26 nondiabetic men and 24 women,
Donahue et al20 identified a high UA loading on a
factor associated with WC, dyslipidemia, insulin
resistance, and BP. In a study of nondiabetic Mauritians,
Hodge et al21 suggested that UA was related to a BP
factor only in men, but not in women. In our study,
UA aggregated with BMI, WC, PG, Log TG, and
HDL-C and loaded on the metabolic factor (Table
5). The model loaded with UA explained a slightly
smaller proportion of the total variance, as did the
model loaded without UA (Tables 4 and 5). The
above findings do not suggest a consistent role of UA
in the metabolic syndrome across different study
populations. The contribution of UA as an additional
component of the syndrome to explain the total
variance also seems to be insignificant from the
results of current factor analysis. We suggested that
the information on UA levels might not be an
important facet to explore the underlying structure
of the metabolic syndrome.
In the study, UA levels were significantly correlated
with Log ALT, and ALT activity predicted the
diagnosis of the metabolic syndrome (Table 3).
Elevated ALT is frequently associated with obesity,
dyslipidemia, and insulin resistance22 and is referred
to as nonalcoholic fatty liver disease (NAFLD) if
other causes of liver enzyme elevation have been
excluded and the subjects have negligible alcohol
intake.23 Marchesini et al24 suggested that NAFLD
could be considered an additional feature of the
metabolic syndrome. They also reported that about
30% of NAFLD patients had both elevated UA and
ALT levels.24 Further studies are warranted for a
better understanding of the constellation of
hyperuricemia and liver enzyme elevation in the
metabolic syndrome.
Although the presence of type 2 diabetes does
not exclude a diagnosis of the metabolic syndrome,15
we focus the study on persons without diabetes. A
uricosuric effect of glycosuria may exist in patients
with diabetes and fasting hyperglycemia, resulting in
a reduced serum UA level in overt diabetic patients.1
In addition, use of antihypertensive agents, especially
diuretics, is known to be associated with increased
levels of UA. Therefore, the participants in the study
were limited to those without diabetes who did not
use antihypertensive agents. There were only 10
participants in the study with WC more than 100 cm.
In Taiwan, the 75 percentile value of WC for middle-
aged men is around 88 cm.25 Asian men with WC *
90 cm are suggested to have abdominal obesity and
to be at risk of comorbidities by the Asian obesity
criteria.14 WC * 90 cm was used in this study for the
diagnosis of the metabolic syndrome by the recently
revised ATP III recommendations.3
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In conclusion, the contribution of UA as an
additional component of the metabolic syndrome
seems to be insignificant to the results of factor analysis.
We propose that hyperuricemia might not be an
important facet for the understanding of the underlying
structure of the metabolic syndrome.
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